Search

You searched for "stone"

1194 results found

In conversation with Ahmed Ali

12 May 2025 | URO - Core Urology
We were delighted to chat to Ahmed Ali about the journey to pursing a urological career in the UK and his decision to found the Arabic-British Urological Society. You grew up in Iraq and went to university in Baghdad; what...

Trials offering cytoreductive surgery for men with de novo synchronous metastatic prostate cancer

8 November 2021 | | URO - Basic Science Research, URO - Urologic Oncology
Life expectancy in men diagnosed with de novo synchronous metastatic hormone-sensitive prostate cancer (mHSPC) has risen to a median of 4.8 years with upfront systemic agents (such as docetaxel) in addition to standard androgen deprivation therapy (ADT) [1-3]. Within this...

Men with a susceptibility to prostate cancer: implications of family history in PCa risk-prediction

3 September 2021 | | URO - Urologic Oncology
Incorporation of family history (FH) status into prostate cancer (PCa) risk stratification has the potential to underpin many aspects of PCa care. This group of men presents a unique challenge in early cancer detection, particularly given that most men without...

Recent advances in the management of castration resistant prostate cancer

1 November 2017 | | URO - Urologic Oncology
Castrate resistant prostate cancer (CRPC) is defined by disease progression despite androgen-deprivation therapy lowering testosterone to castrate levels. It may present as a rise in serum levels of prostate specific antigen (PSA), progression of pre-existing disease, or the appearance of...

Prostate cancer

8 November 2021 | | URO - Urologic Oncology
Case 1 A 65-year-old man is referred to your two-week wait (2WW) clinic with a PSA of 7.0ng/mL. He has no lower urinary tract symptoms (LUTS), no past medical history, no family history of prostate cancer (PCa) and his performance...

Recent developments in bladder cancer – NMIBC

3 May 2022 | | URO - Urologic Oncology
Every year, roughly 10,300 individuals are diagnosed with bladder cancer in the UK, making it the 11th most common cancer in the UK, and the eighth most common cancer in men [1]. Of those diagnosed with the disease, 75-85% will...

The multidisciplinary team meeting: London calling!

1 January 2015 | | URO - Technology
The multidisciplinary team meeting, or MDT, is the foundation of cancer management in the UK. The MDT consists of a group of experts in different fields of medicine and surgery coming together at regular intervals to discuss the diagnosis and...

Urological Complications of Malignancy

1 January 2014 | | URO - Urologic Oncology
Case 1 1. What does this sagittal magnetic resonance imaging (MRI) scan show? 2. Which cancers commonly cause this? 3. What is the acute management? Case 2 1. What is the diagnosis? 2. What local effects can this mass cause?...

Stereotactic body radiotherapy for oligometastatic disease secondary to urological cancer

1 January 2016 | | URO - Urologic Oncology, URO - Technology
The concept of oligometastatic disease is controversial. The traditional model of cancer, which most of us learnt at medical school, is of a disease which starts confined to an organ, for example the prostate, where it can be cured with...

RSM (Royal Society of Medicine) Complexity and Complications: Navigating Advanced Prostate Cancer

21 November 2025
This year’s RSM Cancer Day will focus on the evolving management of prostate cancer. With emerging evidence supporting radical prostatectomy in oligometastatic disease, the programme will examine patient selection, treatment strategies, and the latest advances for managing advanced-stage cases.

Genital gender affirmation surgery for transgender men

5 May 2021 | | URO - Andrology, URO - Functional / Reconstructive Urology
Genital gender affirmation surgery (GAS) is the final step in the transition journey for transgender men. Genital GAS involves a combination of procedures to surgically align physical characteristics with one’s gender identity. These needs change between each individual depending on...

Visual-estimation (cognitive), image-fusion (software) and in-bore targeted prostate biopsy: is there an optimal approach?

3 March 2021 | | URO - Urologic Oncology, URO - Technology
The diagnostic superiority of multiparametric magnetic resonance imaging (mpMRI) prior to targeted and systematic prostate biopsy over systematic transrectal ultrasound-guided (TRUS) biopsy alone in the detection of clinically significant prostate cancer (csPCa) has been proven by multiple level 1 studies...